Skip to main content
Domnica Luca AG Kato

News categories: Publication

Dysregulation of T cell homeostasis

Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling

The research team of Prof. Dr. Hiroki Kato at the Institute of Cardiovascular Immunology is dedicated to understanding the intricate mechanisms of immune responses in the context of viral infections and autoimmune diseases. They are particularly interested in exploring how cytoplasmic RNA sensors, like MDA5, differentiate between viral RNAs and self-RNAs, initiating type I interferons (IFNs) as anti-viral defense. However, mutations in MDA5 can lead to autoimmune diseases. Complementary to that, Domnica Luca et al. recently published her findings in Science Advances with the title "Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling."


Abstract: ADAR1 deficiency constitutively activates MDA5 and causes type I IFN-driven autoimmune diseases. We found a significant reduction in the regulatory T cell (Treg) population in patients with type I interferonopathies caused by mutations in the ADAR1 or IFIH1 gene, encoding MDA5. We analyzed the underlying mechanisms using murine models and found that Treg-specific Adar1 deletion caused peripheral Treg loss and scurfy-like lethal autoimmune disorders. Treg-specific expression of MDA5 gain-of-function mutant also reduced the peripheral Treg population via apoptosis, resulting in severe autoimmune symptoms. However, shut-down of MDA5 signaling in Adar1-deficient Tregs still induced eIF-2α-mediated protein synthesis shut-off, leading to Treg loss and lethality. Altogether, our results highlight the dysregulation of Treg homeostasis in Adar1 deficiency as a key determinant for type I interferonopathies.

Publication:

Luca, D., et al. (2024)

Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling

Science Advances

DOI: 10.1126/sciadv.adk0820

Related news

Dr. Ivana Jorgacevic und Prof. Dr. Rayk Behrendt have discovered that the inflammatory messenger substance interferon-alpha can trigger Sjögren's syndrome: The researchers in Bonn.

News categories: Publication

New test points to precision treatment for autoimmune condition

Interferon alpha is an inflammatory mediator that can cause Sjögren’s syndrome, an autoimmune disease. This is revealed in a recent study carried out by the University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, which have been published in the journal “Lancet Rheumatology,” could make it easier in the medium term to develop drugs to fight this chronic condition.
View entry
Precise Konsortium

News categories: Publication Honors & Funding

Making Cancer Cells More Predictable: PRECISE Aims to Forecast Therapeutically Actionable Vulnerabilities

Which genes and signaling pathways does a cancer cell require to survive? And which of these could serve as therapeutic targets? The pan-European initiative PRECISE aims to identify such vulnerabilities not only through labor-intensive laboratory experiments but also by predicting them using computational models. The UKB and the University of Bonn, represented by Prof. Dr. Maximilian Billmann and Prof. Dr. Jonathan Schmid-Burgk, are among the founding partners of the consortium. The scientific vision of the initiative has now been published in a commentary in Nature Genetics.
View entry
Bild

News categories: Publication

Focus on the Guardians of the Antibody Response

For the immune system to effectively combat pathogens, antibody responses must be precisely controlled. So-called follicular regulatory T cells (Tfr cells) play a key role in this process by limiting excessive immune responses and helping to maintain immune tolerance. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now developed a robust laboratory method that allows Tfr cells to be generated from precursor cells and studied in a targeted manner. The results were recently published in the journal Cellular & Molecular Immunology.
View entry

Back to the news overview